1. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US ): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial 
Joel Gallant, MD, Prof Adriano Lazzarin, MD, Anthony Mills, MD, Chloe Orkin, MD, Daniel Podzamczer, MD, Pablo Tebas, MD, Prof Pierre-Marie Girard, MD, Indira Brar, MD, Eric S Daar, MD, David Wohl, MD, Prof Jürgen Rockstroh, MD, Xuelian Wei, PhD, Joseph Custodio, PhD, Kirsten White, PhD, Dr Hal Martin, MD, Andrew Cheng, MD, Erin Quirk, MD 
The Lancet 
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine.
The Lancet DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2
Proportion of participants with HIV-1 RNA less than 50 copies per mL
Missing-as-excluded analysis. Error bars represent 95% CIs. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine.
The Lancet DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3
Mean percentage change from baseline in hip and lumbar spine bone mineral density
As determined by dual energy X-ray absorptiometry scan. Error bars represent 95% CIs. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. *B/F/TAF versus DTG/ABC/3TC at week 48 by ANOVA.
The Lancet DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions